22.89

1.87% 0.44

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$22.45

Offen:

$22.45

24-Stunden-Volumen:

848.21K

Relative Volume:

0.33

Marktkapitalisierung:

$2.25B

Einnahmen:

$672.72M

Nettoeinkommen (Verlust:

$-575.44M

KGV:

-3.9221

EPS:

-5.8361

Netto-Cashflow:

$-487.00M

1W Leistung:

+18.50%

1M Leistung:

+7.62%

6M Leistung:

-24.25%

1J Leistung:

-29.48%

1-Tages-Spanne:

$22.28

$22.97

1-Wochen-Bereich:

$19.54

$22.97

52-Wochen-Spanne:

$18.29

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Firmenname

Ultragenyx Pharmaceutical Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

415-483-8800

Adresse

60 LEVERONI COURT, NOVATO, CA

Mitarbeiter

1,371

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RARE Ultragenyx Pharmaceutical Inc	22.87	2.21B	672.72M	-575.44M	-487.00M	-5.8361
VRTX Vertex Pharmaceuticals Inc	433.59	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.90	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.75	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.75	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	164.04	35.01B	606.42M	-1.28B	-997.58M	-6.403

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-24	Herabstufung	Goldman	Buy → Neutral
2025-10-20	Eingeleitet	Wells Fargo	Overweight
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2025-05-28	Eingeleitet	William Blair	Outperform
2024-06-06	Hochstufung	Goldman	Neutral → Buy
2024-04-22	Eingeleitet	RBC Capital Mkts	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-06-14	Fortgesetzt	Credit Suisse	Outperform
2023-06-06	Hochstufung	Evercore ISI	In-line → Outperform
2023-04-26	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-18	Fortgesetzt	Canaccord Genuity	Buy
2022-12-30	Fortgesetzt	H.C. Wainwright	Buy
2022-11-03	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-10-13	Hochstufung	Guggenheim	Neutral → Buy
2022-08-01	Herabstufung	Evercore ISI	Outperform → In-line
2022-03-16	Hochstufung	Credit Suisse	Neutral → Outperform
2022-02-11	Hochstufung	JP Morgan	Neutral → Overweight
2021-09-30	Eingeleitet	H.C. Wainwright	Buy
2021-08-19	Eingeleitet	UBS	Sell
2021-07-15	Eingeleitet	Guggenheim	Neutral
2021-06-29	Hochstufung	BofA Securities	Neutral → Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-05-06	Hochstufung	Citigroup	Neutral → Buy
2021-05-06	Hochstufung	Evercore ISI	In-line → Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-03-02	Fortgesetzt	Stifel	Buy
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-07	Herabstufung	Wedbush	Outperform → Neutral
2020-11-24	Fortgesetzt	Evercore ISI	In-line
2020-11-12	Herabstufung	BofA Securities	Buy → Neutral
2019-08-02	Fortgesetzt	Wedbush	Outperform
2019-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Fortgesetzt	Raymond James	Outperform
2019-01-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2018-11-08	Hochstufung	Citigroup	Sell → Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Equal-Weight
2018-06-21	Herabstufung	Credit Suisse	Outperform → Neutral
2018-05-11	Hochstufung	Barclays	Equal Weight → Overweight
2018-05-10	Eingeleitet	Goldman	Neutral
2018-04-18	Hochstufung	SunTrust	Hold → Buy
2018-03-22	Fortgesetzt	Piper Jaffray	Overweight
2018-02-21	Bestätigt	Stifel	Buy
2018-01-22	Hochstufung	Evercore ISI	In-line → Outperform
2018-01-18	Eingeleitet	Credit Suisse	Outperform
2017-12-05	Bestätigt	Barclays	Equal Weight
2017-12-04	Hochstufung	Jefferies	Hold → Buy
2017-09-14	Hochstufung	Wedbush	Neutral → Outperform

Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

10:51 AM

ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. - globenewswire.com

10:51 AM

ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm - GlobeNewswire Inc.

10:51 AM

09:26 AM

RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - 巴士的報

09:26 AM

FinancialContentRARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - FinancialContent

09:26 AM

03:44 AM

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - prnewswire.com

03:44 AM

01:07 AM

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN

01:07 AM

Apr 05, 2026

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - Finansavisen

Apr 05, 2026

RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Norfolk Daily News

Apr 05, 2026